Know the Latest MASH Treatment Options
April 2026
The latest indication for injectable semaglutide (Wegovy) will increase focus on metabolic dysfunction-associated steatohepatitis (MASH).
MASH is when fat builds up in the liver, causing inflammation and liver damage. It’s usually asymptomatic, and if left untreated, it can progress to fibrosis, cirrhosis, liver failure, or death.
MASH often develops in patients with cardiometabolic risk factors, such as obesity, diabetes, hypertension, and dyslipidemia.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive